
## Angélica Castellanos

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11198697/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Randomized clinical trial to assess the protective efficacy of a Plasmodium vivax CS synthetic vaccine. Nature Communications, 2022, 13, 1603.	12.8	9
2	Immunoreactivity of Sera From Low to Moderate Malaria-Endemic Areas Against Plasmodium vivax rPvs48/45 Proteins Produced in Escherichia coli and Chinese Hamster Ovary Systems. Frontiers in Immunology, 2021, 12, 634738.	4.8	7
3	Protective Efficacy of Plasmodium vivax Radiation-Attenuated Sporozoites in Colombian Volunteers: A Randomized Controlled Trial. PLoS Neglected Tropical Diseases, 2016, 10, e0005070.	3.0	50
4	Recombinant Pvs48/45 Antigen Expressed in E. coli Generates Antibodies that Block Malaria Transmission in Anopheles albimanus Mosquitoes. PLoS ONE, 2015, 10, e0119335.	2.5	35
5	Plasmodium vivax Antigen Discovery Based on Alpha-Helical Coiled Coil Protein Motif. PLoS ONE, 2014, 9, e100440.	2.5	10
6	Plasmodium vivax Sporozoite Challenge in Malaria-NaÃ⁻ve and Semi-Immune Colombian Volunteers. PLoS ONE, 2014, 9, e99754.	2.5	52
7	Plasmodium vivax thrombospondin related adhesion protein: immunogenicity and protective efficacy in rodents and Aotus monkeys. Memorias Do Instituto Oswaldo Cruz, 2007, 102, 411-416.	1.6	29
8	INDUCTION OF TRANSMISSION-BLOCKING IMMUNITY IN AOTUS MONKEYS BY VACCINATION WITH A PLASMODIUM VIVAX CLINICAL GRADE PVS25 RECOMBINANT PROTEIN. American Journal of Tropical Medicine and Hygiene, 2005, 73, 32-37.	1.4	38
9	IMMUNOGENICITY AND PROTECTIVE EFFICACY OF RECOMBINANT VACCINE BASED ON THE RECEPTOR-BINDING DOMAIN OF THE PLASMODIUM VIVAX DUFFY BINDING PROTEIN IN AOTUS MONKEYS. American Journal of Tropical Medicine and Hygiene, 2005, 73, 25-31	1.4	51